Skip to main content
Genenta Science S.p.A. logo

Genenta Science S.p.A. — Investor Relations & Filings

Ticker · GNTA ISIN · US36870W1009 LEI · 815600E860D130824E49 US Professional, scientific and technical activities
Filings indexed 86 across all filing types
Latest filing 2025-03-28 Regulatory Filings
Country IT Italy
Listing US GNTA

About Genenta Science S.p.A.

https://www.genenta.com/

Genenta Science is a clinical-stage company developing immuno-oncology therapies based on a proprietary hematopoietic stem cell (HSC) gene therapy platform. The company's technology is designed to reprogram the tumor microenvironment, making solid tumors visible to the immune system and breaking immune tolerance. Its lead candidate, Temferon, aims to deliver therapeutics directly within the tumor mass. The treatment is being investigated as a potential one-time monotherapy and in combination with other approved therapeutics, such as immune checkpoint inhibitors. Clinical development includes a completed Phase 1 trial for Glioblastoma Multiforme and an ongoing Phase 1/2a study in metastatic Renal Cell Carcinoma.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings
2025-03-28 English
Annual Report 2024
Annual Report FY 2024
2025-03-28 English
Regulatory Filings 2025
Regulatory Filings
2025-03-19 English
Regulatory Filings 2025
Regulatory Filings
2025-03-19 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-10 English
Regulatory Filings 2024
Regulatory Filings
2024-12-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.